Akari Therapeutics PLC (AKTX)

AKTX....................................https://stockcharts.com/sc3/ui/?s=AKTX&p=W&b=5&g=0&id=p86431144783

AKTX...$22.52...🥳...Off my $10.76 Alert...All out here...will watch for another entry...

georgie18

Re: georgie18 post# 568

Friday, May 22, 2026 2:21:51 PM

Post#
570
of 572
AKTX...$12.88...🥳

georgie18

Re: None

Friday, May 22, 2026 7:44:25 AM

Post#
568
of 569
AKTX...$10.76...🥳... https://finviz.com/news/356547/akari-therapeutics-reports-breakthrough-preclinical-data-demonstrating-synergistic-activity-of-aktx-101-with-kras-inhibition-in-kras-mutated-pancreatic-cancer-models

AKTX..............................https://stockcharts.com/sc3/ui/?s=AKTX&p=w&b=5&g=0&id=p86431144783

AKTX................https://stockcharts.com/sc3/ui/?s=AKTX&p=w&b=5&g=0&id=p86431144783

AKTX...$12.88...🥳

georgie18

Re: None

Friday, May 22, 2026 7:44:25 AM

Post#
568
of 569
AKTX...$10.76...🥳... https://finviz.com/news/356547/akari-therapeutics-reports-breakthrough-preclinical-data-demonstrating-synergistic-activity-of-aktx-101-with-kras-inhibition-in-kras-mutated-pancreatic-cancer-models

AKTX...............................p/m

AKTX...$10.76...🥳... https://finviz.com/news/356547/akari-therapeutics-reports-breakthrough-preclinical-data-demonstrating-synergistic-activity-of-aktx-101-with-kras-inhibition-in-kras-mutated-pancreatic-cancer-models

AKTX 9.60 WOOOOOOW

Akari Therapeutics to present ADC research at AACR Annual Meeting 2026March 18, 2026 11:02 AM
IH Market News
Akari Therapeutics Plc (NASDAQ:AKTX) said its research has been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, one of the leading global conferences for cancer research. The company’s abstract will be featured as a poster presentation during the event, which will take place April 17–22, 2026.The presentation will focus on the scientific rationale behind the development of a differentiated antibody-drug conjugate (ADC) targeting the Trop2 receptor in solid tumors, including bladder, lung and breast cancers.



Presentation details



The poster will be presented as part of the conference’s Experimental and Molecular Therapeutics program under the session titled “Targeting Cell Surface Vulnerabilities to Overcome Therapeutic Resistance.”




Title: Rationale for the development of a differentiated Trop2 ADC in solid tumors of the bladder, lung, and breast



Poster Number: 3179



Poster Board Number: 14



Session Category: Experimental and Molecular Therapeutics



Session Date and Time: Monday, April 20, 2026 | 2:00 PM – 5:00 PM PT



Location: Poster Section 19




Following the presentation, the poster will be made available on the Posters & Publications section of Akari’s website after 5:00 PM PT on April 20, 2026.Company representatives will also be available to meet with conference attendees during the event.



Focus on next-generation ADC technology



Akari Therapeutics is developing next-generation antibody-drug conjugates designed to deliver targeted cancer therapies using a proprietary RNA splice-modulating payload known as PH1.The company’s lead candidate, AKTX-101, targets the Trop2 receptor found on the surface of certain cancer cells. Using a proprietary linker technology, the drug is designed to deliver the PH1 payload directly into tumor cells while limiting off-target effects.Unlike many current ADC therapies that rely on tubulin inhibitors or DNA-damaging agents, PH1 works by modulating RNA splicing within cancer cells. Preclinical studies suggest this mechanism can disrupt tumor cell survival while also activating components of the immune system, potentially producing durable anti-tumor responses.Animal model research has shown that AKTX-101 may improve survival compared with ADCs that use more traditional payloads. The therapy may also work synergistically with checkpoint inhibitors and has demonstrated activity both as a standalone treatment and in combination with immunotherapies.The PH1 payload has also shown preclinical activity against tumors driven by several oncogenic mutations, including K-RAS G12V, BRAF G466V, AR-V7 and FGFR3 fusions.Akari has begun investigational new drug (IND)-enabling studies for AKTX-101 and is targeting the start of its first-in-human clinical trial in late 2026 or early 2027.



Additional pipeline development



Alongside AKTX-101, the company is also advancing AKTX-102, another antibody-drug conjugate designed to target CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule-5), a tumor antigen commonly expressed across multiple solid tumor types.AKTX-102 also uses Akari’s PH1 spliceosome-modulating payload and proprietary antibody platform, with the aim of improving tumor targeting while enhancing immune activation.Akari Therapeutics is a clinical-stage oncology biotechnology company focused on developing targeted cancer treatments using its ADC discovery platform, which allows the company to design and optimize antibody-drug conjugates for a range of tumor antigens.Akari Therapeutics stock price

Original: Akari Therapeutics to present ADC research at AACR Annual Meeting 2026

AKTX.................................https://stockcharts.com/sc3/ui/?s=AKTX&p=w&b=5&g=0&id=p86431144783

Has demand now,bought some,I still don’t have much faith because shares to short are insane high and it’s not moving freely ,but signs of dilution ending might increase,watching closely

Buys are double the sells,charting up,thru 5 day resistance, 3rd on highest shorted stocks list so could squeeze.
https://investorshub.advfn.com/stock-market/NASDAQ/akari-therapeutics-AKTX/trades

AKTX.........................................https://stockcharts.com/sc3/ui/?s=AKTX&p=w&b=5&g=0&id=p86431144783

AKTX.......................................................https://stockcharts.com/sc3/ui/?s=AKTX&p=W&b=5&g=0&id=p86431144783

AKTX.................................https://stockcharts.com/h-sc/ui?s=AKTX&p=W&b=5&g=0&id=p86431144783

Wouldn't stick around offering still fresh at .80 for 25m

Pump patent .85 get back out .90s  small flipper

AKTX................................................https://stockcharts.com/h-sc/ui?s=AKTX&p=W&b=5&g=0&id=p86431144783

AKTX................................https://stockcharts.com/h-sc/ui?s=AKTX&p=W&b=5&g=0&id=p86431144783

AKTX.................................https://stockcharts.com/h-sc/ui?s=AKTX&p=W&b=5&g=0&id=p86431144783

AKTX.........................................https://stockcharts.com/h-sc/ui?s=AKTX&p=W&b=5&g=0&id=p86431144783

AKTX.......................................https://stockcharts.com/h-sc/ui?s=AXTX&p=W&b=5&g=0&id=p86431144783

AKTX..................................https://stockcharts.com/h-sc/ui?s=AKTX&p=W&b=5&g=0&id=p86431144783

AKTX under $2

Aktx new 52 lo

AKTX new 52 lo

AKTX new 52 lo

News?

Akari Therapeutcis (AKTX) Presesnts Positive Results from Two Preclinical Development Programs of Long-Acting PAS-Nomacopan


Akari Therapeutics, plc (Nasdaq: AKTX) presented positive results from two preclinical studies of its lead asset, investigational nomacopan, in diseases of the eye at the Association of Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting. The two presentations are available at www.investor.akaritx.com/news-and-events/presentations.

“There is significant unmet need in ophthalmology, and we are encouraged by the results of our work so far in the development of long-acting PAS-nomacopan for geographic atrophy,” said Rachelle Jacques, President and CEO of Akari Therapeutics. “This will be an area of focus and investment for Akari as we drive this program forward.”

Development of long-acting PASylated-nomacopan for treatment of GA and other retinal diseases

Geographic atrophy (GA) is a chronic progressive degeneration of the macula, which occurs during late-stage dry age-related macular degeneration (dAMD). Over time, GA can lead to permanent vision loss. It is estimated that more than 8 million people worldwide are affected by GA in AMD and currently there are no approved treatments.

Studies have indicated that while certain complement inhibitors slow the progression of GA, they may also promote choroidal neovascularisation (CNV), which can harm the macula, damage vision,1,2 and require VEGF rescue therapy.

Leukotriene B4 (LTB4) is a potent leukotactic agent that can increase retinal vascular endothelial growth factor (VEGF) a key driver of CNV. Inhibition of LTB4 may decrease the risk of CNV.3 Akari has conducted pre-clinical studies that explore the importance of the LTB4-VEGF axis and the potential role of nomacopan’s bispecific inhibition of both C5 and LTB4 in treating GA/dAMD. In a non-infectious allergic uveitis animal model, PAS-nomacopan reduced VEGF by more than 50% compared to saline control, equivalent to the inhibition caused by an anti-VEGF antibody. In addition, PAS-nomacopan was significantly more effective in reducing retinal inflammation than the anti-VEGF antibody.

One of the pre-clinical studies presented at ARVO 2022 used an industry standard model of laser-induced CNV. Intravitreal (IVT) PAS-nomacopan injected once during a 16-day treatment period was compared to a U.S. Food and Drug Administration-approved VEGF inhibitor for impact on neo-vascularization. The IVT single dose of PAS-nomacopan significantly reduced CNV (p=0.022) as compared to saline and was as effective as multiple IVT injections of the VEGF inhibitor (p=0.019.) Single IVT injection of PAS-nomacopan showed a trend towards reduced leakage on Day 14 (p = 0.097).

Currently approved therapies for retinal diseases injected directly into the vitreous cavity are typically administered monthly. Studies have shown that due to adverse effects (such as an increase in intraocular pressure [IOP]), discomfort and anxiety, IVT injection presents a heavy burden on patients. PASylation of nomacopan has the potential to make it long-lasting in the back of the eye and may provide a dosing interval that is more attractive to patients.

Akari is continuing PK and PD work to optimize PAS-nomacopan with the aim of achieving safety and efficacy in GA, and meeting patient preferences for less frequent injections

Comparison of topical nomacopan, a dual complement and LTB4 inhibitor with dexamethasone in downregulating experimental immune-mediated conjunctival disease (EIC)

Steroid-resistant allergic conjunctivitis, including atopic keratoconjunctivitis (AKC) and vernal keratoconjunctivitis (VKC), is difficult to treat and can lead to corneal scarring and vision loss. Topical or systemic dexamethasone and/or cyclosporin A (CsA) is often required, however dexamethasone may be associated with adverse reactions, including increased IOP.

Topical administration of nomacopan, a therapeutic protein, was recently shown to be effective at attenuating inflammation in a model of experimental immune-mediated conjunctivitis (EIC). The aim of the study presented at ARVO 2022 was to compare the anti-inflammatory effects of nomacopan with topical dexamethasone.

IL-9 expressing mast cells and CD4+T cells are upregulated during ovalbumin (OVA)-induced EIC.

In the preclinical study presented at ARVO 2022, nomacopan preferentially downregulated conjunctival Th2 IL9 producing, Th2 and Th9 CD4+T-cells and nomacopan, dexamethasone and cyclosporinA all effectively decreased Th2 and Th9 cells in draining lymphnodes (dLNs). These findings support use of topical nomacopan to treat allergic eye diseases including VKC and AKC.

References:

Liao DS, et al. Ophthalmology. 2020 Feb;127(2)
Jaffe GJ et al. Ophthalmology. 2021 Apr;128(4)
Sasaki F et al. JCI Insight. 2018 Sep 20;3(18)

$AZN buyout of $ALXN.

$AKTX

$AKTX added.

Lmao. Clueless

Completely doomed company. Nobody touching it! More vol pre-market than trading.

Funny to read the messages from 2 years ago. Same price, sme story. Deals in the making, building in silence. Partnership coming soon. Yeah 24 month later nothing happend. Do not waste your money, this is a dead horse!

yeah, pretty awful.
Long term chart a mess. 4 pump and dumps with lower and lower spikes. now flatline. Everybody is so excited that the constant buying leads to falling prices. Every child knows something is not adding up.

Prices go down when people sell, people sell, when company is shit.

Akari Therapeutics P (AKTX)
1.68 ? 0.03 (1.82%)
Volume: 96,497 @08/27/20 3:35:34 PM EDT
Bid Ask Day's Range
1.67 1.68 1.62 - 1.69
AKTX Detailed Quote

mick, old pump and dumper. Now 10% lower. When is the pump starting or do we make 1000% from 20 cents?

$AKTX Akari Therapeutics P (AKTX)
1.89 ? -0.01 (-0.53%)
Volume: 318,481 @08/07/20 7:53:46 PM EDT
Bid Ask Day's Range
1.86 1.9 1.85 - 1.94
AKTX Detailed Quote

$AKTX BIG TIME MOVE

Added a bunch Friday $AKTX. Have bigly position now. Will wait for double digits to sell. Likely news next week prior to the ER imo

$AKTX Akari Therapeutics PLC (NASDAQ: AKTX): interim update on the Part B placebo-controlled efficacy arm of the study of nomacopan eye drops in atopic keratoconjunctivitis

$AKTX going to be huge runner my friend !!!!!

re;


I was buying $capr at 90¢ and been predicting run like this for weeks. $AKTX will do same or better imo.

Has history of monster runs.

Insiders like chairman own like 50% of the company.

7th richest man in japan holds like 15% of the co.

A doctor from Texas owns 10%+ of the company. OS is 30M.

What size publicly tradable float is left?

Hmmmmmmm $AKTX

ans
thank you

$AKTX i am looking fer $8 plus !!!!!

$AKTX why not this wk ????? biotech are hot item !!!!!

re;
Excellent to see some new posters here.

Give this stock a few months and you will see have a nice movement.

They got the same funding that v k t x recieved.

I saw them move from $1.43 to $23.

I am hoping we have a similar move here at some point.

The science here is very good.

I met the CEO once when they presented in Vancouver.

He is very much a straight shooter.

The majority of the faculty here are Oxford graduates.

All good fellows, with the intention of getting things done right.

ans.
did $AKTX receive funding ????? PPP ?????

$AKTX Akari Therapeutics P (AKTX)
1.97 ? -0.1 (-4.83%)
Volume: 273,514 @07/29/20 6:57:09 PM EDT
Bid Ask Day's Range
1.96 2.02 1.95 - 2.0491
AKTX Detailed Quote

$AKTX I AGREE WITH PPS , EXCELLENT

Agreed. And I'm watching $AKTX for signs to buy more.

Folks don't seem to respond quickly to Biotechs, the
way we do with the more 'sexy stocks'. Bios usually need
hard evidence / data, to get buyer reactions, IMHO.

GLTA

Excellent to see some new posters here. Give this stock a few months and you will see have a nice movement. They got the same funding that v k t x recieved. I saw them move from $1.43 to $23. I am hoping we have a similar move here at some point. The science here is very good. I met the CEO once when they presented in Vancouver. He is very much a straight shooter. The majority of the faculty here are Oxford graduates. All good fellows, with the intention of getting things done right.

$AKTX here you have Akari’s medical director as a presenter for upcoming Covid conference. Obviously he knows he’d have some solid data to present or else they’d have not signed up Akari imo https://complement-therapeutics.com/speaker/wynne-weston-davis/

Meanwhile mkt is clueless Akari even has a Covid program. ?? https://twitter.com/rogerthat191/status/1287970088696463361/photo/1

I was buying $capr at 90¢ and been predicting run like this for weeks. $AKTX will do same or better imo. Has history of monster runs. Insiders like chairman own like 50% of the company. 7th richest man in japan holds like 15% of the co. A doctor from Texas owns 10%+ of the company. OS is 30M. What size publicly tradable float is left? Hmmmmmmm $AKTX